AMZN
Amazon.com, Inc.
AMZN has the edge over THRM overall, supported by stronger modeled upside and stronger valuation.
THRM
Gentherm Incorporated
THRM trails on the overall score without a compensating advantage in the available component scores.
AMZN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Weak | |
| Healthy |
AMZN's revenue, profitability and balance sheet are currently healthy, but its cash flow is weak.
THRM Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Under pressure | |
| Healthy |
THRM's balance sheet is currently healthy, and its revenue and profitability are stable, but its cash flow is under pressure.
AMZN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 22x | $267 | — |
| Forward | 27x | $267 | — |
| Cheap | 34x | $415 | +55% |
| Fair | 60x | $745 | +179% |
| Expensive | 102x | $1,262 | +372% |
Historical ranges are pointers, not guarantees.
AMZN has the edge over THRM in the historical PE scenario, which offers more potential upside but is not a forecast.
THRM PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 10x | $28.79 | — |
| Cheap | 24x | $6.79 | -76% |
| Fair | 36x | $10.21 | -65% |
| Expensive | 62x | $17.38 | -40% |
| Current | 103x | $28.79 | — |
Historical ranges are pointers, not guarantees.
THRM's PE is in its expensive range at 103x. If earnings grow as analysts expect, today's price would be 10x next year's earnings, in its cheap range.
AMZN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong growth | |
| Growth | |
| Improving | |
| Moderate | |
| Moderate |
Analysts expect earnings and revenue growth for AMZN, with profitability improving.
THRM Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect strong earnings and revenue growth for THRM, but weaker profitability. However, they disagree widely on these estimates.
AMZN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $9.87 | -20% |
| Q3 2026 | $12.37 | +75% |
| Q2 2026 | $12.43 | +89% |
| Q1 2026 | $8.36 | +36% |
| Q4 2025 | $7.17 | +30% |
| Q3 2025 | $7.08 | +52% |
| Q2 2025 | $6.56 | +57% |
| Q1 2025 | $6.14 | +72% |
| Q4 2024 | $5.53 | +91% |
AMZN has the edge over THRM on earnings, with more consistent year-over-year improvement.
THRM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.82 | +907% |
| Q3 2026 | $0.28 | -72% |
| Q2 2026 | $0.85 | -16% |
| Q1 2026 | $0.73 | -54% |
| Q4 2025 | $0.59 | -71% |
| Q3 2025 | $0.99 | -54% |
| Q2 2025 | $1.01 | -52% |
| Q1 2025 | $1.59 | +9.7% |
| Q4 2024 | $2.06 | +69% |
THRM's earnings per share have fallen from their peak: $0.28 over the past year, against $3.50 in mid-2021.
AMZN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $201.9B | +12% |
| Q2 2026 | $200.6B | +20% |
| Q1 2026 | $181.5B | +17% |
| Q4 2025 | $213.4B | +14% |
| Q3 2025 | $180.2B | +13% |
| Q2 2025 | $167.7B | +13% |
| Q1 2025 | $155.7B | +8.6% |
| Q4 2024 | $187.8B | +10% |
AMZN has the edge over THRM on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 14% | +4.2 points |
| Q2 2026 | 14% | +2.3 points |
| Q1 2026 | 13% | +1.3 points |
| Q4 2025 | 12% | +0.4 points |
| Q3 2025 | 9.7% | -1.3 points |
| Q2 2025 | 11% | +1.5 points |
| Q1 2025 | 12% | +1.1 points |
| Q4 2024 | 11% | +3.5 points |
AMZN has the edge over THRM on profitability, with a higher operating margin.
THRM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $405.1M | +4.7% |
| Q2 2026 | $416.2M | +11% |
| Q1 2026 | $393.7M | +11% |
| Q4 2025 | $382.8M | +8.5% |
| Q3 2025 | $386.9M | +4.1% |
| Q2 2025 | $375.1M | -0.2% |
| Q1 2025 | $353.9M | -0.6% |
| Q4 2024 | $352.9M | -3.8% |
THRM's revenue has grown year over year for five quarters in a row: $405M last quarter, up 4.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | -2.6 points |
| Q2 2026 | 2.6% | -3.8 points |
| Q1 2026 | 2.9% | -2 points |
| Q4 2025 | 4.6% | -2.1 points |
| Q3 2025 | 6.2% | -2.5 points |
| Q2 2025 | 6.4% | -2.4 points |
| Q1 2025 | 4.8% | -0.3 points |
| Q4 2024 | 6.7% | -1.9 points |
THRM's operating margin was 3.5% last quarter, down 2.6 points from the same quarter a year ago.
AMZN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$34.8B | -8202% |
| Q2 2026 | -$8.8B | -2757% |
| Q1 2026 | -$18.2B | -$10.2B |
| Q4 2025 | $14.9B | -16% |
| Q3 2025 | $430M | -87% |
| Q2 2025 | $332M | -96% |
| Q1 2025 | -$8B | -297% |
| Q4 2024 | $17.8B | -36% |
AMZN's free cash flow was −$46.9B over the past year, against $10.6B the year before.
THRM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $25.4M | -45% |
| Q2 2026 | -$1.2M | -103% |
| Q1 2026 | -$10.7M | +$17.5M |
| Q4 2025 | $6.7M | -51% |
| Q3 2025 | $46.5M | +75% |
| Q2 2025 | $36.2M | +104% |
| Q1 2025 | -$28.2M | -$6.6M |
| Q4 2024 | $13.6M | -52% |
THRM has the edge over AMZN on cash generation, producing positive trailing cash flow while its opponent burns cash.
AMZN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +26M shares |
| 1 year | +0.8% | +84M shares |
| 3 years | +3.5% | +371M shares |
| 5 years | +6.1% | +629M shares |
| Available history | +8.2% | +829M shares |
AMZN has 10.9B diluted shares, up 0.8% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | $3.3B |
THRM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.2% | -382K shares |
| 1 year | -0.2% | -76K shares |
| 3 years | -7.6% | -2.5M shares |
| 5 years | -8.7% | -2.9M shares |
| Available history | -7.9% | -2.6M shares |
THRM has the edge over AMZN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $10M |
| Q1 2025 | — |
| Q4 2024 | $10M |
| Q3 2024 | $19.9M |
| Q4 2023 | $60M |
| Q3 2023 | $11.1M |
AMZN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.7x | Very low |
| Q2 2026 | 0.3x | Very low |
| Q1 2026 | 0.1x | Very low |
| Q4 2025 | -0.1x | Net Cash |
| Q3 2025 | -0.1x | Net Cash |
| Q2 2025 | -0.0x | Net Cash |
| Q1 2025 | -0.1x | Net Cash |
| Q4 2024 | -0.2x | Net Cash |
AMZN's net debt is less than a year of its operating earnings (EBITDA), after holding more cash than debt a year ago.
THRM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.6x | Very low |
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.3x | Very low |
| Q4 2025 | 0.2x | Very low |
| Q3 2025 | 0.3x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.6x | Very low |
| Q4 2024 | 0.5x | Very low |
THRM has the edge over AMZN on leverage, with a lower net debt burden relative to earnings.
AMZN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.1 | Neutral |
| Stochastic | 50.0 | Neutral |
AMZN's weekly RSI is 57 (neutral) and its Stochastic is 50 (neutral).
THRM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.9 | Neutral |
| Stochastic | 23.1 | Neutral |
THRM's weekly RSI is 38 (neutral) and its Stochastic is 23 (neutral).
AMZN PE vs Consumer Cyclical Sector
| Metric | AMZN | Sector median | Relative |
|---|---|---|---|
| PE | 22x | 18x | 20% above |
| PE % | 4 | 47 | 43 pts below |
AMZN has the edge over THRM on valuation relative to its sector.
THRM PE vs Consumer Cyclical Sector
| Metric | THRM | Sector median | Relative |
|---|---|---|---|
| PE | 103x | 18x | 471% above |
| PE % | 96 | 47 | 49 pts above |
THRM is trading at 103x earnings, a 471% premium to the Consumer Cyclical sector's median of 18x.
AMZN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $253.6 | 5.5% above |
| 20 week MA | $254.9 | 4.9% above |
| 50 week MA | $242.5 | 10% above |
| 100 week MA | $229.6 | 17% above |
| 200 week MA | $191.4 | 40% above |
AMZN has the edge over THRM on trend strength, trading above more of its moving averages.
THRM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $30.4 | 5.2% below |
| 20 week MA | $35.7 | 19% below |
| 50 week MA | $34.1 | 16% below |
| 100 week MA | $33.4 | 14% below |
| 200 week MA | $43.3 | 33% below |
THRM is in a downtrend: it's below all five of its weekly moving averages, and 33% below its 200-week average.
AMZN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $93.5 | $158.6 | +70% |
| 2021 | $158.6 | $171.1 | +7.8% |
| 2022 | $171.1 | $85.3 | -50% |
| 2023 | $85.3 | $151.9 | +78% |
| 2024 | $151.9 | $223.8 | +47% |
| 2025 | $223.8 | $232.5 | +3.9% |
| 2026 YTD | $232.5 | $267.4 | +15% |
AMZN has the edge over THRM on returns for 2026, with the stronger performance.
THRM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $44.3 | $66.0 | +49% |
| 2021 | $66.0 | $82.4 | +25% |
| 2022 | $82.4 | $63.8 | -23% |
| 2023 | $63.8 | $52.4 | -18% |
| 2024 | $52.4 | $39.0 | -25% |
| 2025 | $39.0 | $37.2 | -4.7% |
| 2026 YTD | $37.2 | $28.8 | -23% |
THRM has finished four years in a row lower, and it's down 23% so far in 2026.